Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Cancer ; 10(4): 957-967, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30854102

RESUMO

Purpose: Trophinin-associated protein (TROAP) is a cytoplasmic protein that plays a significant role in the processes of embryo transplantation and microtubule regulation. However, the relevant survival analysis and cancer progression analysis have not yet been reported. Methods: Eighteen matched pairs of tumor and adjacent non-tumor samples were evaluated to detect the TROAP mRNA level. Immunohistochemistry (IHC) was used to evaluate the TROAP expression in 108 hepatocellular carcinoma patients who underwent surgical resection. Meanwhile, data from the TCGA database was statistically evaluated. Results: In the present study, we detected a significant increase in the TROAP mRNA level in tumor tissues when compared with adjacent non-tumor tissues. Moreover, the upregulation of TROAP was associated with increased serum AFP and GGT; the greater the tumor number was, the larger the tumor size, differentiation grade, and cancer embolus in clinical analysis. In HCC patients, elevated TROAP expression in the primary tumor was positively related to clinical severity, such as poor overall survival and disease-free survival. In addition, both univariate and multivariate survival analysis validated that TROAP expression was a promising independent risk factor for overall survival and disease-free survival in HCC patients. Furthermore, the results derived from the analysis of data from the TCGA database were consistent with previous results. Altogether, our results show that TROAP is a novel crucial regulator of HCC progression and is a potential therapeutic biomarker for HCC patients. Conclusions: Elevated TROAP expression predicted a poor prognosis, and TROAP may serve as a potential biomarker for application in oncotherapy.

2.
J Colloid Interface Sci ; 525: 216-224, 2018 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-29704781

RESUMO

Pt-based bimetallic nanocrystals are feasible to dramatically improve the catalytic performances in fuel cells via morphology- and composition-engineering. Herein, bimetallic platinum69-cobalt31 nanosheet nanoassemblies (Pt69Co31 NSNSs) were facilely synthesized through a one-pot co-reduction solvothermal strategy in oleylamine (OAm), using cetyltrimethylammonium chloride (CTAC) and allantoin as the directing agents. The current synthesis highly depended on the critical concentrations of Pt and Co precursors, the combined use of allantoin to OAm as the co-reductant, and the use of proper allantoin concentration. The obtained nanocatalyst exhibited largely enhanced electrocatalytic activity and durable ability towards ethylene glycol oxidation reaction (EGOR) and oxygen reduction reaction (ORR) relative to home-made Pt85Co15 nanoparticles (NPs), Pt19Co81 NPs and Pt black catalysts due to its much larger electrochemically active surface area than the contrasts.

3.
J Huazhong Univ Sci Technolog Med Sci ; 36(2): 237-242, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27072969

RESUMO

The aim of this study is to evaluate the efficacy of total saponins of Dioscorea (TSD), an extract of the Chinese herbal Bi Xie, on hyperuricemia and to elucidate the underlying mechanisms. The rat hyperuricemia model was established by administration of adenine. Thirty-two rats were randomly allocated into 4 groups: model group, low/high-dose TSD-treated groups, and allopurinol-treated group. Meanwhile, 8 rats were used as normal controls. Serum uric acid (UA), blood urea nitrogen (BUN), serum creatinine (Scr), and organic anion transporting polypeptide 1A1 (OATP1A1) levels were measured. Comparison between the model group and treatment (allopurinol and TSD) groups showed the serum UA levels were significantly decreased in treatment groups. TSD had similar effects to allopurinol. It was found that the OATP1A1 protein expression levels in treatment groups were higher than in model group and normal controls. And different from the allopurinol-treated groups, TSD-treated group had elevated OATP1A1 expression levels in the stomach, liver, small intestine and large intestine tissues. It was suggested that TSD may facilitate the excretion of UA and lower UA levels by up-regulating OATP1A1 expression.


Assuntos
Dioscorea/química , Medicamentos de Ervas Chinesas/farmacologia , Hiperuricemia/tratamento farmacológico , Transportadores de Ânions Orgânicos Sódio-Independentes/metabolismo , Saponinas/farmacologia , Ácido Úrico/sangue , Animais , Creatinina/sangue , Medicamentos de Ervas Chinesas/uso terapêutico , Mucosa Gástrica/metabolismo , Mucosa Intestinal/metabolismo , Intestinos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Transportadores de Ânions Orgânicos Sódio-Independentes/genética , Ratos , Ratos Sprague-Dawley , Saponinas/uso terapêutico , Estômago/efeitos dos fármacos , Regulação para Cima
4.
BMC Cancer ; 14: 505, 2014 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-25011933

RESUMO

BACKGROUND: Few studies consider both the survival and financial benefits of detection of invasive cervical cancer (ICC) at earlier stages. This study estimated the savings in life-years and costs from early diagnosis of cervical cancer using an ex post approach. METHODS: A total of 28,797 patients diagnosed with cervical cancer in the period 2002-2009 were identified from the National Cancer Registry of Taiwan, and linked to the National Mortality Registry until the end of 2011. Life expectancies (LE) for cancer at different stages were estimated using a semi-parametric extrapolation method. The expected years of life lost (EYLL) for cancer were calculated by subtracting the LE of the cancer cohort from that of the age-and sex-matched general population. The mean lifetime costs after diagnosis paid by the single-payer National Health Insurance during (NHI) 2002-2010 were estimated by multiplying average monthly expenditures by the survival probabilities and summing up over lifetime. RESULTS: ICC at stages 1 to 4 had an average EYLL of 6.33 years, 11.64 years, 12.65 years, and 18.61 years, respectively, while the related lifetime costs paid by the NHI were $7,020, $10,133, $11,120, and $10,015 US dollars, respectively; the younger the diagnosis age, the higher the savings with regard to EYLL. The mean lifetime costs of managing cervical cancer were generally lower for the earlier stages compared with stages 3 and 4. CONCLUSIONS: Early detection of ICC saves lives and reduces healthcare costs. These health benefits and monetary savings can be used for cost-effectiveness assessments and the promotion of regular proactive screening, especially among older women.


Assuntos
Detecção Precoce de Câncer/economia , Detecção Precoce de Câncer/métodos , Neoplasias do Colo do Útero/diagnóstico , Idoso , Análise Custo-Benefício , Bases de Dados Factuais , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Sistema de Registros , Análise de Sobrevida , Taiwan/epidemiologia , Neoplasias do Colo do Útero/epidemiologia , Neoplasias do Colo do Útero/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA